Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments.

Clinical trials Community-acquired pneumonia Core outcome set End points Evidence-based medicine Hospital-acquired pneumonia Outcomes Pneumonia Systematic reviews Ventilator-associated pneumonia

Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 30 05 2023
revised: 18 10 2023
accepted: 18 10 2023
pubmed: 29 10 2023
medline: 29 10 2023
entrez: 28 10 2023
Statut: ppublish

Résumé

To inform clinical practice guidelines, randomized controlled trials (RCTs) of the management of pneumonia need to address the outcomes that are most important to patients and health professionals using consistent instruments, to enable results to be compared, contrasted, and combined as appropriate. This systematic review describes the outcomes reported in clinical trials of pneumonia management and the instruments used to measure these outcomes. Based on a prospective protocol, we searched MEDLINE/PubMed, Cochrane CENTRAL and clinical trial registries for ongoing or completed clinical trials evaluating pneumonia management in adults in any clinical setting. We grouped reported outcomes thematically and classified them following the COMET Initiative's taxonomy. We describe instruments used for assessing each outcome. We found 280 eligible RCTs of which 115 (41.1%) enrolled critically ill patients and 165 (58.9%) predominantly noncritically ill patients. We identified 43 distinct outcomes and 108 measurement instruments, excluding nonvalidated scores and questionnaires. Almost all trials reported clinical/physiological outcomes (97.5%). Safety (63.2%), mortality (56.4%), resource use (48.6%) and life impact (11.8%) outcomes were less frequently addressed. The most frequently reported outcomes were treatment success (60.7%), mortality (56.4%) and adverse events (41.1%). There was significant variation in the selection of measurement instruments, with approximately two-thirds used in less than 10 of the 280 RCTs. None of the patient-reported outcomes were used in 10 or more RCTs. This review reveals significant variation in outcomes and measurement instruments reported in clinical trials of pneumonia management. Outcomes that are important to patients and health professionals are often omitted. Our findings support the need for a rigorous core outcome set, such as that being developed by the European Respiratory Society.

Identifiants

pubmed: 37898460
pii: S0895-4356(23)00271-8
doi: 10.1016/j.jclinepi.2023.10.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

88-95

Investigateurs

Stefano Aliberti (S)
Aleksandra Barac (A)
Francesco Blasi (F)
Jean Chastre (J)
Mike Clarke (M)
Catia Ciloniz (C)
Paul Dark (P)
George Dimopoulos (G)
Markus Fally (M)
Timothy W Felton (TW)
Andrea Gramegna (A)
Jan Hansel (J)
Faiuna Haseeb (F)
Ahmed Kouta (A)
Alexander G Mathioudakis (AG)
Eva Polverino (E)
Claire Roger (C)
Rebecca C Robey (RC)
Nikoletta Rovina (N)
Daiana Stolz (D)
Jørgen Vestbo (J)
Grant Waterer (G)
Tobias Welte (T)
Thomas Williams (T)
Paula R Williamson (PR)
Dan G Wootton (DG)
Geffen van Wouter (G)

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest related to this work.

Auteurs

Alexander G Mathioudakis (AG)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK; North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. Electronic address: alexander.mathioudakis@manchester.ac.uk.

Markus Fally (M)

Department of Respiratory Medicine and Infectious Diseases, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.

Jan Hansel (J)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK; North West School of Intensive Care Medicine, Health Education England North West, Manchester, UK.

Rebecca C Robey (RC)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK; North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Faiuna Haseeb (F)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.

Thomas Williams (T)

Acute Intensive Care Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Ahmed Kouta (A)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.

Tobias Welte (T)

Department of Respiratory Medicine and German Centre of Lung Research (DZL), Hannover Medical School, Hanover, Germany.

Dan G Wootton (DG)

Institute of Infection, Veterinary and Ecological Sciences, NIHR HPRU in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK.

Mike Clarke (M)

Centre of Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.

Grant Waterer (G)

School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, Western Australia, Australia.

Paul Dark (P)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.

Paula R Williamson (PR)

Department of Health Data Science, MRC/NIHR Trials Methodology Research Partnership, University of Liverpool, Liverpool, UK.

Jørgen Vestbo (J)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK; North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Timothy W Felton (TW)

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK; North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Acute Intensive Care Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Classifications MeSH